What is the Impact of Early Life Exposures on the Cardiovascular System in Young Adulthood? (EVS)
The purpose of this study is to investigate whether early life exposures such as premature birth or exposure to preeclampsia before you are born results in long-term alterations in the cardiovascular system that increase risk of cardiovascular disease development.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||What is the Impact of Early Life Exposures on the Cardiovascular System in Young Adulthood? A 25-Year Follow-up Study of Preterm-born Individuals|
whole blood, serum, plasma, immortalised cell lines
|Study Start Date:||May 2007|
|Estimated Study Completion Date:||October 2015|
|Estimated Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
|Preterm-born Young Adults|
|Term-born Young Adults|
While the incidence of cardiovascular disease has reduced dramatically, coinciding with favourable changes in risk factors, cardiovascular disease remains the single largest cause of mortality and premature mortality in the United Kingdom. Identification of novel biological pathways that underlie disease susceptibility raises the potential for new early primary prevention strategies to complement classical management. There is particular interest in the role of early environment in 'programming' risk of cardiovascular disease in later life and growing evidence that various early life exposures impact cardiovascular health in the longer term.
We have thus designed the Early Vascular Study to investigate the long-term impact of early life exposures, with a particular focus on the impact of preterm birth, in the presence or absence of pregnancy-induced hypertension in the mother, on the cardiovascular system in young adulthood. This study also allows investigation of the long term impact of perinatal interventions used in this cohort. Comprehensive multi-modality non-invasive imaging measures of cardiovascular structure and function allow precise quantification of cardiovascular phenotype. This is combined with blood sample collection to study changes in molecular and metabolic markers and pathways.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01487824
|Contact: Paul Leeson, PhD, MRCP||+44(0)email@example.com|
|Contact: Adam Lewandowski, BSc (Hons)||+44(0)firstname.lastname@example.org|
|Cardiovascular Clinical Research Facility, Dept of Cardiovascular Medicine, University of Oxford||Recruiting|
|Oxford, Oxfordshire, United Kingdom, OX3 9DU|
|Contact: Paul Leeson, PhD, FRCP +441865572846 email@example.com|
|Sub-Investigator: Adam J Lewandowski, BSc(Hons)|
|Principal Investigator:||Paul Leeson, PhD, MRCP||Oxford Cardiovascular Clinical Research Facility, Department of Cardiovascular Medicine, University of Oxford|